drugset / Trial / NCT00917813
A Study of Anti-HIV Monoclonal Antibody KD-247
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247 over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters of KD-247 when administered as above; and to assess the effect of KD-247 infusions on plasma HIV-1 ribonucleic acid (RNA) load and on CD4+ T cell counts.
Timeline
- Start
- 2007-09
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KD-247 | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | KD-247 | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | KD-247 | Monoclonal antibody | 16 mg/kg | Intravenous |